Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2013

01-11-2013 | Review Article

Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients

Authors: Siri Beier Jensen, Virginia Jarvis, Yehuda Zadik, Andrei Barasch, Anura Ariyawardana, Allan Hovan, Noam Yarom, Rajesh V. Lalla, Joanne Bowen, Sharon Elad, For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)

Published in: Supportive Care in Cancer | Issue 11/2013

Login to get access

Abstract

Purpose

The aim of this systematic review was to analyze the available literature and define clinical practice guidelines for the use of the following agents for the prevention and treatment of oral mucositis (OM): allopurinol, midline mucosa-sparing radiation blocks, payayor, pentoxifylline, timing of radiation therapy (RT) (morning versus late afternoon), pilocarpine, bethanechol, chewing gum, propantheline, and tetrachlorodecaoxide.

Methods

A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, no guideline possible.

Results

A total of 32 papers across 10 interventions were examined. New suggestions were developed against the use of systemic pilocarpine administered orally for prevention of OM during RT in head and neck cancer patients and in patients receiving high-dose chemotherapy, with or without total body irradiation, prior to hematopoietic stem cell transplantation. A suggestion was also made against the use of systemic pentoxifylline administered orally for the prevention of OM in patients undergoing bone marrow transplantation. No guideline was possible for any other agent reviewed due to inadequate and/or conflicting evidence.

Conclusions

None of the agents reviewed was determined to be effective for the prevention or treatment of OM. Two agents, pilocarpine and pentoxifylline, were determined to be ineffective, in the populations listed above. Additional well-designed research is needed on other interventions.
Literature
1.
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831PubMedCrossRef
2.
Lalla RV (2013) The MASCC/ISOO mucositis guidelines update: introduction to the first set of articles. Support Care Cancer 21(1):301–302PubMedCrossRef
3.
Bowen JM, Elad S, Hutchins RD, Lalla RV (2013) Methodology for the MASCC/ISOO mucositis clinical practice guidelines update. Support Care Cancer 21(1):303–308PubMedCrossRef
4.
Elad S, Bowen J, Zadik Y, Lalla RV (2013) Development of the MASCC/ISOO clinical practice guidelines for mucositis: considerations underlying the process. Support Care Cancer 21(1):309–312PubMedCrossRef
5.
Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM (2013) Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21(1):313–326PubMedCrossRef
6.
Nicolatou-Galitis O, Sarri T, Bowen J, Di PM, Kouloulias VE, Niscola P, Riesenbeck D, Stokman M, Tissing W, Yeoh E, Elad S, Lalla RV (2013) Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 21(1):357–364
7.
Migliorati C, Hewson I, Lalla RV, Antunes HS, Estilo CL, Hodgson B, Lopes NN, Schubert MM, Bowen J, Elad S (2013) Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 21(1):333–341PubMedCrossRef
8.
Peterson DE, Ohrn K, Bowen J, Fliedner M, Lees J, Loprinzi C, Mori T, Osaguona A, Weikel DS, Elad S, Lalla RV (2013) Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer 21(1):327–332PubMedCrossRef
9.
Raber-Durlacher JE, von Bültzingslöwen I, Logan RM, Bowen J, Al-Azri AR, Everaus H, Gerber E, Gomez JG, Pettersson BG, Soga Y, Spijkervet FK, Tissing WJ, Epstein JB, Elad S, Lalla RV (2013) Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer 21(1):343–355PubMedCrossRef
10.
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49(7):749–754PubMedCrossRef
11.
Somerfield MR, Einhaus K, Hagerty KL, Brouwers MC, Seidenfeld J, Lyman GH (2008) American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol 26(24):4022–4026PubMedCrossRef
12.
Yarom N, Ariyawardana A, Hovan A, Barasch A, Jarvis V, Jensen SB, Zadik Y, Elad S, Bowen J, Lalla RV, For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) (2013) Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer. doi:10.​1007/​s00520-013-1869-5
13.
Howell SB, Wung WE, Taetle R, Hussain F, Romine JS (1981) Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48(6):1281–1289PubMedCrossRef
14.
Kroener JF, Saleh F, Howell SB (1982) 5-FU and allopurinol: toxicity modulation and phase II results in colon cancer. Cancer Treat Rep 66(5):1133–1137PubMed
15.
Howell SB, Pfeifle CE, Wung WE (1983) Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 51(2):220–225PubMedCrossRef
16.
Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, Fujimoto T, Watanabe K, Ogawa K (2004) Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Res 24(2C):1131–1134PubMed
17.
Panahi Y, Ala S, Saeedi M, Okhovatian A, Bazzaz N, Naghizadeh MM (2010) Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis. Eur J Cancer Care (Engl) 19(3):308–312CrossRef
18.
Loprinzi CL, Cianflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM, Hagen L, Gainey DK, Cross M, Athmann LM (1990) A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 65(8):1879–1882PubMedCrossRef
19.
Clark PI, Slevin ML (1985) Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. Eur J Surg Oncol 11(3):267–268PubMed
20.
Tsavaris N, Caragiauris P, Kosmidis P (1988) Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes. Eur J Surg Oncol 14(5):405–406PubMed
21.
Tsavaris NB, Komitsopoulou P, Tzannou I, Loucatou P, Tsaroucha-Noutsou A, Kilafis G, Kosmidis P (1991) Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil. Sel Cancer Ther 7(3):113–117PubMedCrossRef
22.
Elzawawy A (1991) Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes. Oncology 48(4):282–284PubMedCrossRef
23.
Van der Vliet W, Erlichman C, Elhakim T (1989) Allopurinol mouthwash for prevention of fluorouracil-induced stomatitis. Clin Pharm 8(9):655–658
24.
Porta C, Moroni M, Nastasi G (1994) Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 17(3):246–247PubMedCrossRef
25.
Perch SJ, Machtay M, Markiewicz DA, Kligerman MM (1995) Decreased acute toxicity by using midline mucosa-sparing blocks during radiation therapy for carcinoma of the oral cavity, oropharynx, and nasopharynx. Radiology 197(3):863–866PubMed
26.
Putwatana P, Sanmanowong P, Oonprasertpong L, Junda T, Pitiporn S, Narkwong L (2009) Relief of radiation-induced oral mucositis in head and neck cancer. Cancer Nurs 32(1):82–87PubMedCrossRef
27.
Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, Laurent G, Pris J (1993) Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 82(3):732–736PubMed
28.
Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW (1991) Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78(5):1205–1211PubMed
29.
van der Jagt RH, Pari G, McDiarmid SA, Boisvert DM, Huebsch LB (1994) Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 13(2):203–207PubMed
30.
Ferra C, de Sanjose S, Lastra CF, Marti F, Marino EL, Sureda A, Brunet S, Gallardo D, Berlanga JJ, Garcia J, Granena A (1997) Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 20(12):1075–1080PubMedCrossRef
31.
Stockschlader M, Kalhs P, Peters S, Zeller W, Kruger W, Kabisch H, Lechner K, Zander A (1993) Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 12(4):357–362PubMed
32.
Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T (1995) A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80(1):36–42PubMedCrossRef
33.
Goyal M, Shukla P, Gupta D, Bisht SS, Dhawan A, Gupta S, Pant MC, Verma NS (2009) Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study. Int J Radiat Biol 85(6):504–509PubMedCrossRef
34.
Bjarnason GA, Mackenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, Brundage M, Wright J, Hay J, Ganguly P, Leong C, Wilson J, Jordan RC, Walker M, Tu D, Parulekar W (2009) Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys 73(1):166–172PubMedCrossRef
35.
Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, Jackson W, Delapenha RA, Shiroky J, Baum BJ (1991) Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151(6):1149–1152PubMedCrossRef
36.
Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, Meredith R, Foote R, Brachman D, Lee N (2006) Effect of pilocarpine during radiation therapy: results of RTOG 97–09, a phase III randomized study in head and neck cancer patients. J Support Oncol 4(5):252–258PubMed
37.
Warde P, O’Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J, Payne D, Bayley A, Ringash J, Kim J, Liu FF, Maxymiw W, Sprague S, Cummings BJ (2002) A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 54(1):9–13PubMedCrossRef
38.
Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC, Frenette G (2005) Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant 35(7):713–720PubMedCrossRef
39.
Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al QA, Jamhoury A, Daniel M, Charles C, Ambrose A, El-Aloosy AS (2001) Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. Eur J Cancer 37(16):2010–2014PubMedCrossRef
40.
Jham BC, Chen H, Carvalho AL, Freire AR (2009) A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. JOral Sci 51(4):565–572
41.
Gandemer V, Le Deley MC, Dollfus C, Auvrignon A, Bonnaure-Mallet M, Duval M, De LL, Hartmann O, Mechinaud F, Sirvent N, Orbach D, Doireau V, Boutard P, Dalle JH, Reguerre Y, Pautard B, Aubier F, Schneider P, Suc A, Couillaut G, Schmitt C (2007) Multicenter randomized trial of chewing gum for preventing oral mucositis in children receiving chemotherapy. J Pediatr Hematol Oncol 29(2):86–94PubMedCrossRef
42.
Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P, Corbi D, Puccio C, Chun H, Mittelman A (1993) Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 12(2):131–132PubMed
43.
Oblon DJ, Paul SR, Oblon MB, Malik S (1997) Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant 20(11):961–963PubMedCrossRef
44.
Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M (2006) Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku J Exp Med 210(4):315–320PubMedCrossRef
45.
Malik IA, Moid I, Haq S, Sabih M (1997) A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis. J Pain Symptom Manage 14(2):82–87PubMedCrossRef
46.
Schwartz PM, Handschumacher RE (1979) Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (allopurinol) in vitro. Cancer Res 39(8):3095–3101PubMed
47.
Berne M, Gustavsson B, Almersjo O, Spears CP, Waldenstrom J (1987) Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2’-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver. Cancer Chemother Pharmacol 20(3):193–197PubMedCrossRef
48.
Pedersen AM, Bardow A, Jensen SB, Nauntofte B (2002) Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis 8(3):117–129PubMedCrossRef
49.
Vissink A, Mitchell JB, Baum BJ, Limesand KH, Jensen SB, Fox PC, Elting LS, Langendijk JA, Coppes RP, Reyland ME (2010) Clinical management of salivary gland hypofunction and xerostomia in head and neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys 78(4):983–991PubMedCrossRef
50.
Jensen SB, Mouridsen HT, Reibel J, Brünner N, Nauntofte B (2008) Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncology 44(2):162–173PubMedCrossRef
51.
Amaral TMP, Campos CC, Santos TPM, Leles CR, Teixeira AL, Teixeira MM, Bittencourt H, Silva TA (2012) Effect of salivary stimulation therapies on salivary flow and chemotherapy-induced mucositis: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol 113(5):628–637CrossRef
Metadata
Title
Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients
Authors
Siri Beier Jensen
Virginia Jarvis
Yehuda Zadik
Andrei Barasch
Anura Ariyawardana
Allan Hovan
Noam Yarom
Rajesh V. Lalla
Joanne Bowen
Sharon Elad
For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1884-6

Other articles of this Issue 11/2013

Supportive Care in Cancer 11/2013 Go to the issue

Special Article

Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results

Original Article

Couple distress after localised prostate cancer

Original Article

Day One Talk: parent preferences when learning that their child has cancer

Original Article

Satisfaction with information and its association with illness perception and quality of life in Indonesian breast cancer patients

Original Article

Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion

Editorial

The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits